Epilepsy, Temporal Lobe Clinical Trial
Official title:
Epilepsy Surgery and Cognition, Psychiatric Function and Quality of Life - Outcome 10 Years or More After Surgery
NCT number | NCT04264780 |
Other study ID # | 651421 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | August 15, 2019 |
Est. completion date | October 30, 2023 |
Verified date | October 2023 |
Source | Oslo University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study will give important information about long term consequences of temporal lobe epilepsy surgery on cognition (memory, language, concentration etc), psychiatric function and quality of life.
Status | Completed |
Enrollment | 102 |
Est. completion date | October 30, 2023 |
Est. primary completion date | October 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 30 Years and older |
Eligibility | Inclusion Criteria: - Prior temporal lobe epilepsy surgery (10 years ago or more) Exclusion Criteria: - Intelligence quotient (IQ) less than 70 - Other main language than Norwegian |
Country | Name | City | State |
---|---|---|---|
Norway | Oslo University Hospital, Spesialsykehuset for epilepsi | Oslo |
Lead Sponsor | Collaborator |
---|---|
Oslo University Hospital |
Norway,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in each study group on neuropsychological tests of memory from baseline (preoperative) to current evaluation | Memory will be measured by Rey Auditory Verbal Learning Test, results reported as raw scores from 1-worst to 15-best; and Diagnosticum für Cerebralschädugung-Revised - DCS-R, results reported as raw scores from 1-worst to 15-best. All results will be converted to T-scores with average 50, standard deviation 10. | During single data collection session, aproximately 2 hours | |
Primary | Change in each study group on neuropsychological tests of language from baseline (preoperative) to current evaluation | Language will be measured by the subtest "Similarities" from Wechsler Adult Intelligence Scale - WAIS-III, results reported as raw scores from 1-worst to 33-best; Boston Naming Test-results reported as raw scores from 1-worst to 60-best; Letter Fluency from Delis Kaplan Executive Function Scale-D-KEFS, raw scores from 1-worst and up. All results will be converted to T-scores. | During single data collection session, aproximately 2 hours | |
Primary | Change in each study group on neuropsychological tests of visuospatial abilities from baseline (preoperative) to current evaluation | Visuospatial abilities will be measured by the subtest "Block Design" from WAIS-III, raw scores from 1-worst to 68-best. Results will be converted to T-scores. | During single data collection session, aproximately 2 hours | |
Primary | Change in each study group on neuropsychological tests of executive function from baseline (preoperative) to current evaluation | Executive function will be measured by the subtest "Digit Span" from WAIS-III, raw scores from 1-worst, to 30-best; Trails A and B from Halstead test battery, raw scores from 1-worst and up. All results will be converted to T-scores. | During single data collection session, aproximately 2 hours | |
Secondary | Score on depression questionaire | Beck Depression Inventory (raw scores divided in 4 categories: 0-13 minimal depression, 14-19 mild depression, 20-28 moderate depression and 29-63 serious depression). | During single data collection session, aproximately 2 hours | |
Secondary | Score on anxiety questionaire | Beck Anxiety Inventory (raw scores divided in 4 categories: 0-7 minimal anxiety, 8-15 mild anxiety, 16-25 moderate anxiety and 26-63 serious anxiety). | During single data collection session, aproximately 2 hours | |
Secondary | Score on quality of life inventory | Quality of Life in Epilepsy - QUOLIE 89 - results will be reported as overall score ranging from 26-worst, to 95-best, and converted to T-score with average 50, standard deviation 10) | During single data collection session, aproximately 2 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00001672 -
Language Localization Using Repetitive Transcranial Magnetic Stimulation (rTMS) in Patients With Epilepsy
|
N/A | |
Active, not recruiting |
NCT04897776 -
Stimulation of the Thalamus for Arousal Restoral in Temporal Lobe Epilepsy
|
N/A | |
Recruiting |
NCT05947656 -
Evaluation of the NaviFUS System in Drug Resistant Epilepsy
|
N/A | |
Not yet recruiting |
NCT06036732 -
A New Approach in Intensive Care Unit Consciousness Assessment: FIVE Score
|
||
Recruiting |
NCT04164056 -
Hippocampal and Thalamic DBS for Bilateral Temporal Lobe Epilepsy
|
Phase 4 | |
Completed |
NCT03265925 -
Brain Network Activation Analysis in Epilepsy
|
||
Enrolling by invitation |
NCT02151175 -
Low-intensity Focused Ultrasound Pulsation (LIFUP) for Treatment of Temporal Lobe Epilepsy
|
N/A | |
Recruiting |
NCT03478852 -
Investigating Epilepsy: Screening and Evaluation
|
||
Recruiting |
NCT01273129 -
Surgery as a Treatment for Medically Intractable Epilepsy
|
||
Not yet recruiting |
NCT06057233 -
Innovative MRI to Localize the Epileptic Zone
|
||
Withdrawn |
NCT02913742 -
The Utility of NIOM During LITT for Refractory MTLE
|
N/A | |
Recruiting |
NCT04649008 -
Localizing Epileptic Networks Using MRI and iEEG
|
Early Phase 1 | |
Completed |
NCT00931619 -
GABA/Glutamate Balance in Temporal Lobe Epilepsy With and Without Major Depression
|
||
Recruiting |
NCT04717388 -
Pathophysiology, Psycho-emotional and Cognitive Functioning Associated With Tinnitus
|
N/A | |
Completed |
NCT00706160 -
Language Mapping in Patients With Epilepsy
|
||
Recruiting |
NCT05339438 -
Pre-operative Mapping of the Anterior Temporal Lobe Using Functional MRI Innovative Techniques in in Drug-resistant Epileptic Patients
|
N/A | |
Not yet recruiting |
NCT04871555 -
Structural Cartography of the Insula in Temporal Epilepsy Patients
|
||
Completed |
NCT04169581 -
A Deep Learning Framework for Pediatric TLE Detection Using 18F-FDG-PET Imaging
|
||
Completed |
NCT00040326 -
Early Surgical Intervention to Treat Epilepsy
|
Phase 3 | |
Not yet recruiting |
NCT06422923 -
Effect of NRTX-1001, a Cellular Therapy Product, for the Treatment of Refractory Bilateral TLE
|
Phase 1 |